** Shares of drugmaker Bristol Myers Squibb BMY.N fall 3.9% to $57.39 premarket
** Co forecasts 2025 revenue of around $45.5 billion, below analysts' average expectation of $47.4 billion - LSEG data
** Sees 2025 EPS between $6.55 and $6.85 per share, below estimates of $6.92
** BMY expects generic competition for some of its older drugs
** Co is expanding its cost-cutting program by additional $2 billion by end of 2027, bringing total cost cuts under the program to $3.5 billion
** Stock rose ~10% in 2024
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。